Structural Biology Program
The Jonathan Goldberg Lab
Our research group studies the mechanisms of protein trafficking and quality control at the endoplasmic reticulum (ER) in mammalian cells. A major focus of research is on the COPII protein machinery responsible for synthesis of ER-derived transport vesicles. We are exploring the mechanisms utilized by COPII to segregate folded protein cargo from unfolded forms and ER chaperones. We are exploring the coordination of this process with quality control systems that evaluate the folded state. A second focus of research is the cellular response to ER proteotoxicity arising in neurodegenerative disorders such as Parkinson’s disease, in cancer, and in insulin resistance. We are studying the protective cellular pathways that detect and clear toxic misfolded proteins via ER and post-ER degradative routes.
Jonathan Goldberg, PhD
Stephen and Barbara Friedman Chair
- The Goldberg laboratory focuses on structural and biochemical characterization of intracellular vesicle transport.
- PhD, Imperial College (London)
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jonathan Goldberg discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.